CLEVELAND – What are some of the biggest challenges related using to artificial intelligence (AI) in health care? A panel of experts tackled that question during a session Tuesday during the 2019 Medical Innovations Summit, while also discussing what their organizations have done in this space to advance patient care.
Palo Alto, Calif.-based startup Doc.ai is training its sights on the $9.5 billion global epilepsy market, with the aim of using artificial intelligence to help patients find the best medication to control their seizures. To that end, the company is teaming up with the Stanford University School of Medicine and the Stanford Epilepsy Center on a digital health trial to develop a predictive treatment model that will identify the right treatment at the right time for individuals living with epilepsy.
Mayo Clinic has entered a 10-year partnership with Google "to expand on the more than 200 projects already incorporating artificial intelligence (AI) and machine learning," Mayo Chief Medical Information Officer Steve Peters told BioWorld MedTech. The Rochester, Minn.-based health care organization expects Google's expertise in data science and search technology will help the clinic improve treatment and outcomes by developing machine learning models.
The field of artificial intelligence (AI) in medical practice is in its infancy, but a group of medical societies has published a paper that proposes the development of a code of ethics for artificial intelligence (AI) in radiology. The paper underscores a number of concerns, including that some developers fail to fully appreciate the potential consequences of seemingly innocent slip-ups in the development and validation of that algorithm.
LONDON – The first systematic review and meta-analysis of the accuracy of artificial intelligence in health care has concluded AI may be as good as clinicians in interpreting medical images, but it is hard to be sure because of the poor quality of published studies. Researchers at Birmingham University, U.K. considered 31,887 journal papers appearing between January 2012 and June 2019, of which 20,530 were screened. They found most were methodologically flawed.
Evaxion Biotech A/S is leveraging two artificial intelligence (AI) platforms to quickly identify targets for cancer immunotherapies and infectious diseases.
PERTH, Australia – There is pervasive use of artificial intelligence and machine learning (AI/ML) across the health care industry in Australia, and excitement is building on the opportunities it offers to technologies and ultimately to patients, Ausbiotech CEO Lorraine Chiroiu told BioWorld Asia.
RSS
